M
Michael R. Robinson
Researcher at Allergan
Publications - 193
Citations - 13436
Michael R. Robinson is an academic researcher from Allergan. The author has contributed to research in topics: Bimatoprost & Intraocular pressure. The author has an hindex of 44, co-authored 183 publications receiving 12479 citations. Previous affiliations of Michael R. Robinson include National Institutes of Health & Government of the United States of America.
Papers
More filters
Journal ArticleDOI
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley,John R. Wunderlich,Paul F. Robbins,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Nicholas P. Restifo,Amy M. Hubicki,Michael R. Robinson,Mark Raffeld,Paul H. Duray,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +18 more
TL;DR: The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Journal ArticleDOI
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley,John R. Wunderlich,James Chih-Hsin Yang,Richard M. Sherry,Suzanne L. Topalian,Nicholas P. Restifo,Richard E. Royal,Udai S. Kammula,Donald E. White,Sharon Mavroukakis,Linda J. Rogers,Gerald J. Gracia,Stephanie Jones,David P. Mangiameli,Michelle M. Pelletier,Juan Gea-Banacloche,Michael R. Robinson,David Berman,Armando C. Filie,Andrea Abati,Steven A. Rosenberg +20 more
TL;DR: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma.
Journal ArticleDOI
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
Peter Attia,Giao Q. Phan,Ajay V. Maker,Michael R. Robinson,Martha Quezado,James Chih-Hsin Yang,Richard M. Sherry,Suzanne L. Topalian,Udai S. Kammula,Richard E. Royal,Nicholas P. Restifo,Leah R. Haworth,Catherine Levy,Sharon Mavroukakis,Geoff M. Nichol,Michael Yellin,Steven A. Rosenberg +16 more
TL;DR: Administration of anti-CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.
Journal ArticleDOI
Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Careen Y. Lowder,Rubens Belfort,Susan Lightman,C. Stephen Foster,Michael R. Robinson,Rhett M. Schiffman,Xiao-yan Li,Harry Cui,Scott M. Whitcup +8 more
TL;DR: In patients with noninfectious intermediate or posterior uveitis, a single DEX implant significantly improved intraocular inflammation and visual acuity persisting for 6 months.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.
Joan-En Chang-Lin,Mayssa Attar,Andrew Acheampong,Michael R. Robinson,Scott M. Whitcup,Baruch D. Kuppermann,Devin F. Welty +6 more
TL;DR: In this article, the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.).